ClinicalTrials.gg
Not yet recruitingNCT07935135ASCENDUpdated Nov 13, 2026

Study of CMP-002 in Participants With SYNGAP1-Related Disorder

A Phase 1/2 interventional study of CMP-002 and Sham-prick in Nervous System Disease, sponsored by CAMP4 Therapeutics Corporation. Not yet recruiting at 1 site in Argentina. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by CAMP4 Therapeutics Corporation · Phase 1/2, Interventional, and Treatment

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Study summary

The primary purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of CMP-002 in participants with SYNGAP1-related disorder.

Read the detailed description

ASCEND is a global, Phase 1/2, multicenter, randomized, double-blind (Sponsor-open), controlled, multiple-ascending dose (MAD) study to assess the safety, tolerability, and pharmacokinetics, of CMP-002 in participants with SYNGAP1-related disorder (SRD). The study consists of a Baseline Period in which participants will undergo screening assessments to establish the baseline for clinical study assessments. The Baseline Period is followed by a Treatment Period consisting of 3 planned dose level cohorts wherein each participant will receive 3 doses of CMP-002 administered intrathecally (IT) or a control procedure on Days 1, 29, and 85. Each dose level cohort includes a minimum of 8 participants randomized in a 3:1 ratio (CMP-002: control). Following the completion of Dose 3, participants will be followed for an additional 24 weeks in the Follow-up Period.

02

Conditions studied

  • Nervous System Disease

Keywords

  • SYNGAP1-related disorder
03

In context

Nervous System Diseases

758 studies on the registry are indexed under Nervous System Diseases; 217 are open to participants now.

This study's planned enrollment of 80 is above the median of 55 across 496 interventional studies indexed under Nervous System Diseases.

Browse Nervous System Diseases studies →

Lead sponsor

CAMP4 Therapeutics Corporation is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written and/or assent, according to local guidelines
  • Participant is ≥2 and \<18 years of age at the time of informed consent/assent
  • Participants must have a clinical diagnosis of a SYNGAP1-related disorder. For entry into the treatment period, genetic confirmation (specifically, of protein truncating mutations in SYNGAP1 exons 5-19) is required. The following mutations in SYNGAP1 exons 5-19 are acceptable:

    1. Frameshift mutations
    2. Nonsense mutations
  • Ability to comply with the protocol and trial procedures detailed in the Schedule of Assessments (SoA)
  • Participant has phenotype consistent with haploinsufficiency
  • Participants must be taking at least one maintenance ASM, have not made changes to ASMs dose or frequency for 6 weeks prior to entering the Baseline Period, and not be planning to change their anti-seizure regimen throughout the study
  • For entry into Treatment Period: All maintenance ASMs and interventions for seizures, as well as any cannabinoid-based products, must have been stable (weight-related adjustments are allowed) during the Baseline Period

Exclusion criteria

Exclusion Criteria:

  • Participant has an exon 1-4, non-truncating mutation, missense mutations, and microdeletions that include the SYNGAP1 gene
  • Participant's prior genetic test indicates a pathogenic or likely pathogenic variant in a gene other than SYNGAP1 (the pathogenic or likely pathogenic variant must be homozygous in cases of known recessive disease)
  • Participant's genetic test indicates SYNGAP1 variant of unknown significance (VUS), mosaicism or additional genetic diagnoses
  • Participant has a history of central nervous system (CNS) disease (other than epilepsy or SRD), including history of bacterial or viral meningitis or brain malformation
  • History of intolerance of IT administration, including intolerance to lumbar puncture
  • For entry into the Treatment Period: Participant has a spinal deformity or other condition that may alter the free flow of CSF or has an implanted CSF drainage shunt. Note: Participants with scoliosis or spinal rods are not excluded if, in the judgement of the Investigator, lumbar puncture can be performed and there is free flow of CSF.
  • Participant has laboratory results outside of the normal ranges at screening and judged as by the Investigator for liver function (including GGT, , aspartate aminotransferase, alkaline phosphatase), kidney function (creatinine, urea), and
  • Positive viral serology test results for type 1 or 2 antibodies, surface antigen or virus (HCV) antibody
  • Participant has participated in any other interventional clinical study of an gene therapy, or participant is currently participating in or has participated in a clinical study involving an investigational medicinal product within 2 months (or 5 half-lives, whichever is longer) prior to Screening
  • Participant is currently using or plans to use unapproved or experimental medicinal products or cannabinoid or cannabidiol or supplemental products, including acetyl-leucine related products
  • Participant is using anticoagulants and antiplatelet agents; and is unwilling or unable to discontinue use per standard of care prior to and after the lumbar puncture dosing Day 1
  • Participant has any other symptomatology of SRD disease or any disease or disorder, including a clinically significant unstable medical condition, CNS disease (other than epilepsy), or brain malformation, which in the opinion of the Investigator, may either put the participant at risk because of participation in the study including consideration of sedation procedures, may influence the results of the study, or may affect the participant's ability to participate in the study.
  • Participant has known to the of the investigational medicinal product.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    CMP-002 Multiple Ascending Dose (MAD)

    Participants will be administered CMP-002 on Days 1, 29, and 85, and will be followed for 24 weeks after the last dose. Three dose levels will be evaluated.

    Drug: CMP-002

  • Sham comparator
    Sham-prick

    Participants will receive the sham-prick procedure on Days 1, 29, and 85, and will be followed for 24 weeks after the last procedure.

    Other: Sham-prick

Interventions

  • DrugCMP-002

    CMP-002 is an antisense oligonucleotide that will be administered by IT injection.

  • OtherSham-prick

    The sham-prick procedure involves no injection/puncture or penetration of the dura, but only a skin prick with a needle.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of multiple doses of CMP-002: incidence of adverse events and changes from baseline in clinical laboratory results

    Time frame: Screening to Week 36

Secondary outcomes

  1. CSF concentrations of the active drug substance of CMP-002 after multiple doses

    Time frame: Day 1 to Week 36

  2. Plasma PK of the active drug substance of CMP-002 after multiple doses: Cmax

    Time frame: Day 1 to Day 85

  3. Plasma PK of the active drug substance of CMP-002 after multiple doses: AUC(0-24h)

    Time frame: Day 1 to Day 85

  4. Urine PK of the active drug substance of CMP-002: Cmax

    Time frame: Day 1

  5. Urine PK of the active drug substance of CMP-002: AUC(0-24hr)

    Time frame: Day 1

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jan 2029, 26 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 13, 2026
StartEst.
Nov 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07935135
Lead sponsor
CAMP4 Therapeutics Corporation
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

CAMP4 Therapeutics Clinical Trials Information
Contact
medinfo@camp4tx.com
617-651-8867

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion